Abstract 4384: Does progressive disease justify pembrolizumab discontinuation: a simulation analysis
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-4384
Abstract: Background: With checkpoint inhibition becoming first line therapy in several cancer indications, there is a growing number of patients that are refractory to PD1 therapy. It is unclear if these patients should remain on PD1… read more here.
Keywords: justify pembrolizumab; progression; virtual patients; progressive disease ... See more keywords